Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
Shah
Prediman K
PK
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications; D001241:Aspirin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism* / Q000502:physiology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D013925:Thromboplastin / Q000502:physiology; D013927:Thrombosis / Q000209:etiology*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D008074:Lipoproteins; D010975:Platelet Aggregation Inhibitors; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin; D013925:Thromboplastin; D001241:Aspirin